Evidence map›Paper›PMID 38534210›Full record

ArticleAntibodies (Basel, Switzerland)2024

Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (

Brian Effer, Daniel Ulloa, Camila Dappolonnio, Francisca Muñoz, Isabel Iturrieta-González, Loraine Cotes, Claudio Rojas, Pamela Leal

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Brian EfferCenter of Excellence in Translational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0000-0002-2339-2049
Daniel UlloaCarrera de Biotecnología, Facultad de Ciencias Agropecuarias y Medioambiente, Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0009-0000-9172-1871
Camila DappolonnioCarrera de Biotecnología, Facultad de Ciencias Agropecuarias y Medioambiente, Universidad de La Frontera, Temuco 4811230, Chile.
Francisca MuñozCarrera de Biotecnología, Facultad de Ciencias Agropecuarias y Medioambiente, Universidad de La Frontera, Temuco 4811230, Chile.
Isabel Iturrieta-GonzálezCenter of Excellence in Translational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0000-0001-8426-9530
Loraine CotesCarrera de Ingeniería Pesquera, Facultad de Ingeniería, Universidad del Magdalena, Carrera 32 No. 2208 Sector San Pedro Alejandrino, Santa Marta 470001, Colombia.
Claudio RojasPrograma de Doctorado en Ciencias Médicas, Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0000-0001-8938-2532
Pamela LealCenter of Excellence in Translational Medicine (CEMT) and Scientific and Technological Bioresource Nucleus (BIOREN), Universidad de La Frontera, Temuco 4811230, Chile.
Universidad de La Frontera · CLUniversity of Magdalena · CO

Funding

Agencia Nacional de Investigación y Desarrollo Fomento a la vinculación internacional para instituciones de investigación Folio FOVI230029Agencia Nacional de Investigación y Desarrollo Fondecyt de Iniciación Folio 11240028Agencia Nacional de Investigación y Desarrollo Fondecyt de Postdoctorado Folio 3210142Agencia Nacional de Investigación y Desarrollo Fondecyt Regular Folio 1201734Universidad de La Frontera DIRFRO PAT23-0017Universidad de La Frontera DIUFRO DI230073
6 · The paper itself

Abstract

Gallbladder cancer (GBC) is a very aggressive malignant neoplasm of the biliary tract with a poor prognosis. There are no specific therapies for the treatment of GBC or early diagnosis tools; for this reason, the development of strategies and technologies that facilitate or allow an early diagnosis of GBC continues to be decisive. Phage display is a robust technique used for the production of monoclonal antibodies (mAbs) involving (1) the generation of gene libraries, (2) the screening and selection of isoforms related to an immobilized antigen, and (3) the in vitro maturation of the affinity of the antibody for the antigen. This research aimed to construct a human immune library from PBMCs of GBC patients and the isolation of

Indexed as

claudin 18.2gallbladder cancerimmune librarymonoclonal antibodyphage display

Identifiers

PMID38534210
PMCPMC10967586
OpenAlexW4392698150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.